Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Sikkerhed og præstationer af LINEA-hjertepacingledningen optimeret til implantation i interventrikulært septum (STARLIGHT)

18. september 2026 opdateret af: MicroPort CRM

Sikkerhed og præstationer for LINEA-kardiopacemakerledningen optimeret til implantation i interventrikulært septum

The purpose of the clinical investigation is to evaluate the safety and performances of the new LINEA cardiac pacing lead, intended for placement at the interventricular septum.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

450

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion criteria (phase I and II):

  • Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)
  • Patient planned for a de novo implantation of an ALIZEA, BOREA or CELEA Single Chamber (SR) or Dual Chamber (DR) pacemaker from MicroPort CRM
  • Patient planned for a catheter-guided ventricular pacing lead implantation in the interventricular septum area
  • Patient's pacemaker with the remote monitoring functions accepted by the patient and planned to be activated

Exclusion criteria (phase I and II):

  • Patient planned for a device upgrade, or a device or a lead replacement
  • Patient with a congenital heart disease, hypertrophic cardiomyopathy or infiltrative cardiomyopathy
  • Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%
  • Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
  • Patient having a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient for whom a single dose of steroid eluted by the pacing lead (e.g., dexamethasone sodium phosphate) is contraindicated, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
  • Patient with a life expectancy of less than 2 years
  • Minor age patient (i.e. under 18 years of age)
  • Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
  • Non-menopausal women

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: LINEA kardiak pacemaker-ledning

Use of LINEA cardiac pacing lead and delivery catheter for implantation of pacemaker

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
LINEA lead complication free rate at 3 months
Tidsramme: 3 months after implantation

Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death

3 months after implantation
LINEA lead pacing threshold amplitude at 3 months
Tidsramme: 3 months after implantation

Mean ventricular pacing threshold amplitude

3 months after implantation

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Success rate of LINEA lead minimum sensed amplitude
Tidsramme: 3 months after implantation

Proportion of patients with minimum sensed amplitude ≥ 5 mV

3 months after implantation
General performances of LINEA lead
Tidsramme: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation

Pacing threshold amplitude, impedance and minimum sensed amplitude obtained with the LINEA lead at each patient's visit. LBB pacing threshold amplitude obtained with the LINEA lead during implantation, as well as the chronaxie measurement

Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
Safety of the LINEA lead
Tidsramme: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation

LINEA lead complication free rate over time, calculated based on number of Adverse Events and Device Deficiencies related to the lead

Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
Safety of the FLEXIGO delivery catheter and the FLEXIGO slitter
Tidsramme: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation

FLEXIGO catheter complication free rate, calculated based on number of Adverse Events and Device Deficiencies related to the catheter or the slitter

Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
LINEA lead implantation success rates
Tidsramme: Implantation

Proportion of LINEA leads implanted in the interventricular septum and meeting or not LBBAP criteria

Implantation
Lead and delivery catheter implantation time
Tidsramme: Implantation

Total procedural time and total fluoroscopic time of each implantation

Implantation
LINEA lead and FLEXIGO delivery catheter and slitter implantation usability
Tidsramme: Implantation

Handling scores based on a specific questionnaire (scale Very poor/Poor/Acceptable/Good/Very good)

Implantation
Right Ventricular Autothreshold performances
Tidsramme: 3 months after implantation

- Accuracy - Comparison between the manual ventricular pacing threshold performed by a physician and the in-clinic ventricular pacing threshold provided by the RVAT function at the same pulse width and during the same on-site patient's visit

3 months after implantation
Evolution of LBBAP capture over time
Tidsramme: 18 months after implantation

- LBBAP capture evolution with analyses of ECGs (i.e. V6 R-wave peak time and V6-V1 interpeak interval) and LBBAP criteria collected

18 months after implantation

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Early outcome - Absence of Unanticipated Serious Adverse Device Effect (USADE) related to LINEA lead
Tidsramme: 1 month after implantation

Proportion of patients free from USADE. Any event caused by use of the LINEA lead or any accessory packaged with the lead, will be considered as an ADE related to the LINEA lead. The endpoint evaluation will be based on an independent safety events adjudication from a Clinical Events Committee (CEC), based on investigational site reporting

1 month after implantation
Early outcome - LINEA lead pacing threshold amplitude at 1 month
Tidsramme: 1 month after implantation

Mean ventricular pacing threshold amplitude

1 month after implantation
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Tidsramme: 1 month after implantation

- Implantation success rate - Proportion of LINEA lead successfully implanted at the interventricular septum and fulfilling or not LBBAP success criteria according to the operator's decision

1 month after implantation
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Tidsramme: 1 month after implantation

- Short term electrical performances variation - Pacing threshold variation between implantation and 1 month, and electrical performances of the LINEA lead (pacing threshold, impedance and minimum sensed amplitude)

1 month after implantation
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Tidsramme: 1 month after implantation

- Complication free rate - Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death

1 month after implantation

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

23. juni 2026

Primær færdiggørelse (Anslået)

31. januar 2027

Studieafslutning (Anslået)

30. april 2030

Datoer for studieregistrering

Først indsendt

26. november 2025

Først indsendt, der opfyldte QC-kriterier

5. januar 2026

Først opslået (Faktiske)

15. januar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • LLAI01 - STARLIGHT

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner